The world´s population is currently confronted with the unusual and unpredictable situation of the rapidly spreading COVID-19 infection caused by the new coronavirus SARS-CoV-2. Severe course of respiratory infection, often with high mortality, is a threat especially for the elderly persons with comorbidities. Hemophilia and congenital bleeding disorders do not cause increased susceptibility to infection or severe disease progression. However, there may be a risk of failure to provide or delay adequate treatment of the underlying disease during the pandemics in this group of patients who are dependent on replacement therapy for missing coagulation factors also produced from human resources.

Coronavirus is spread by a droplet infection and has not been confirmed to be transmitted by blood and blood products. In addition, the size of the virus and its lipid envelope make the virus highly sensitive to fractionation and virus-inactivation processes used in the production of coagulation factor concentrates. In this work we present basic safety issues and principles of treatment of patients with hemophilia and bleeding disorders in order to maintain an adequate level of treatment and comprehensive care for this group of patients during COVID-19 pandemics.

Key words: COVID-19 pandemics, hemophilia, congenital coagulopathies, treatment safety.
Lek Obz, 2020, 69 (7 – 8): 230-234


Slovenská hemofilická pracovná skupina SHaTS SLS, Národné hemofilické centrum – Európske hemofilické centrum komplexnej starostlivosti (EHCCC) a Expertízne pracovisko pre liečbu hemofílie a vrodených krvácavých ochorení v SR, KHaT LF UK, SZU a UNB, Bratislava, prednosta prof. MUDr. A. Bátorová, CSc.